Image
Lifting the Bar in Severe Asthma Translating Pathophysiologic Insights Into New Targeted Therapies

Michael E. Wechsler, MD, MMSc

This activity is jointly provided by Global Education Group and Integritas Communications.

 

This educational activity is supported by an educational grant from AstraZeneca.

Faculty

Michael E. Wechsler, MD, MMSc
Professor, Department of Medicine
Director, The Cohen Family Asthma Institute
Divistion of Pulmonary, Critical Care and Sleep Medicine
Director, Asthma Program
National Jewish Health
Denver, Colorado

Program Description

Biologic therapies that target upstream mediators of disease constitute a rapidly growing field within the clinical treatment landscape of severe asthma. Therefore, best practices for the use of these novel therapies, including placement within treatment algorithms, comprise an important aspect of management. This CME Circuit Training™ activity has been designed to flex your knowledge and build your clinical management muscles. Utilizing a unique multimedia platform that consists of three 15-minute circuits, our faculty will guide you through a series of workouts that will boost your endurance and strengthen your expertise within the management of severe asthma. 

Target Audience

The educational design of this activity addresses the needs of allergists/clinical immunologists, and other clinicans who manage patients with severe asthma.

Learning Objectives

After completing this activity, participants will be better prepared to:

  • Discuss key aspects of severe asthma pathophysiology, including thymic stromal lymphopoietin (TSLP), epithelial inflammation, airway hyperresponsiveness, and implications for treatment
  • Describe the clinical profiles and recent trial results with newer biologic therapies for severe asthma
  • Tailor therapeutic regimens for patients with severe asthma using newer biologic treatments to reduce symptoms, prevent exacerbations, decrease systemic corticosteroid use, and reflect shared clinical decision-making

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.75 contact hour(s) (which includes 0.0 hour(s) of pharmacology).

Disclosure of Conflicts of Interest

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Michael E. Wechsler, MD, MMSc - Consultant: Amgen Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Cerecor Inc., Cohero Health, CytoReason LTD, Equillium, Inc.,  Genentech, Inc., Genzyme Corporation, Inc., GlaxoSmithKline plc, Incyte Corporation, Kinaset Therapeutics, Novartis Pharmaceuticals Corp., Regeneron Pharmaceuticals, Inc., resTORbio Inc., sanofi-aventis U.S. LLC, Sentien Biotechnologies, Inc., Sound Biologic, Teva Pharmaceutical Industries Ltd.; Honoraria: Amgen Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Cerecor Inc., Cohero Health, CytoReason LTD, Equillium, Inc., Genentech, Inc., Genzyme Corporation, Inc., GlaxoSmithKline plc, Incyte Corporation, Kinaset Therapeutics, Novartis Pharmaceuticals Corp., Regeneron Pharmaceuticals, Inc., resTORbio Inc.,  sanofi-aventis U.S. LLC , Sentien Biotechnologies, Inc., Sound Biologic, Teva Pharmaceuticals Industries Ltd.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must review the activity as well as successfully complete the posttest, by achieving a score of 70% or higher, and evaluation form.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Global Education Group Contact Information

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 0.75

credit type CME/AANP

release 06/29/2022

expiration 06/29/2023